Go back

IP sharing brings boost for neglected diseases

Anglo-Swedish drug company AstraZeneca signed an agreement with three research organisations last month to develop drugs for neglected tropical diseases.

The three agreements are the first project to come out of the World Intellectual Property Organization’s Re:Search initiative, which was launched last October. It allows companies to make available assets such as drug candidates and related technologies to qualified researchers on a royalty-free basis.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.